Antiviral therapies on the horizon for influenza

Current Opinion in Pharmacology

Volumn 30, Issue , 2016, Pages 106-115

  Naesens, Lieve ^a   Stevaert, Annelies ^a   Vanderlinden, Evelien ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AL 794; ANA 1; ASN 2; COMPOUND 1; COMPOUND 7; CR 8020; CURCUMIN; DIRIDAVUMAB; FAVIPIRAVIR; L 742001; MHAA 4549A; NAPROXEN; NITAZOXANIDE; NUCLEOZIN; OSELTAMIVIR; PROTEIN INHIBITOR; SIALIDASE INHIBITOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; UNCLASSIFIED DRUG; VIS 410; VX 787; ANTIVIRUS AGENT; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BINDING SITE; CLINICAL PRACTICE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DNA FRAGMENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; HOSPITALIZATION; INFLUENZA; MOLECULAR DYNAMICS; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; DRUG DESIGN; EPIDEMIC; HUMAN; IMMUNOLOGY; INFLUENZA, HUMAN; PANDEMIC; VIROLOGY;

ANTIVIRAL AGENTS; CRYSTALLOGRAPHY; DISEASE OUTBREAKS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS;

EID: 84983604572     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.08.003     Document Type: Review

References (65)

1. 1 Dawood, F.S., Iuliano, A.D., Reed, C., Meltzer, M.I., Shay, D.K., Cheng, P.Y., Bandaranayake, D., Breiman, R.F., Brooks, W.A., Buchy, P., Feikin, D.R., Fowler, K.B., Gordon, A., Hien, N.T., Horby, P., Huang, Q.S., Katz, M.A., Krishnan, A., Lal, R., Montgomery, J.M., Mølbak, K., Pebody, R., Presanis, A.M., Razuri, H., Steens, A., Tinoco, Y.O., Wallinga, J., Yu, H., Vong, S., Bresee, J., Widdowson, M.A., Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12 (2012), 687–695.
2. 2 Takashita, E., Meijer, A., Lackenby, A., Gubareva, L., Rebelo-de-Andrade, H., Besselaar, T., Fry, A., Gregory, V., Leang, S.K., Huang, W., Lo, J., Pereyaslov, D., Siqueira, M.M., Wang, D., Mak, G.C., Zhang, W., Daniels, R.S., Hurt, A.C., Tashiro, M., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antiviral Res 117 (2015), 27–38.
3. 3 Jefferson, T., Jones, M.A., Doshi, P., Del Mar, C.B., Hama, R., Thompson, M.J., Spencer, E.A., Onakpoya, I., Mahtani, K.R., Nunan, D., Howick, J., Heneghan, C.J., Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev, 4, 2014, CD008965.
4. 4 Dobson, J., Whitley, R.J., Pocock, S., Monto, A.S., Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 385 (2015), 1729–1737.
5. 5 Muthuri, S.G., Venkatesan, S., Myles, P.R., Leonardi-Bee, J., Al Khuwaitir, T.S., Al Mamun, A., Anovadiya, A.P., Azziz-Baumgartner, E., Báez, C., Bassetti, M., Beovic, B., Bertisch, B., Bonmarin, I., Booy, R., Borja-Aburto, V.H., Burgmann, H., Cao, B., Carratala, J., Denholm, J.T., Dominguez, S.R., Duarte, P.A., Dubnov-Raz, G., Echavarria, M., Fanella, S., Gao, Z., Gérardin, P., Giannella, M., Gubbels, S., Herberg, J., Iglesias, A.L., Hoger, P.H., Hu, X., Islam, Q.T., Jiménez, M.F., Kandeel, A., Keijzers, G., Khalili, H., Knight, M., Kudo, K., Kusznierz, G., Kuzman, I., Kwan, A.M., Amine, I.L., Langenegger, E., Lankarani, K.B., Leo, Y.S., Linko, R., Liu, P., Madanat, F., Mayo-Montero, E., McGeer, A., Memish, Z., Metan, G., Mickiene, A., Mikić, D., Mohn, K.G., Moradi, A., Nymadawa, P., Oliva, M.E., Ozkan, M., Parekh, D., Paul, M., Polack, F.P., Rath, B.A., Rodríguez, A.H., Sarrouf, E.B., Seale, A.C., Sertogullarindan, B., Siqueira, M.M., Skręt-Magierło, J., Stephan, F., Talarek, E., Tang, J.W., To, K.K., Torres, A., Törün, S.H., Tran, D., Uyeki, T.M., Van Zwol, A., Vaudry, W., Vidmar, T., Yokota, R.T., Zarogoulidis, P., Nguyen-Van-Tam, J.S., Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2 (2014), 395–404.
6. 6•• Nguyen-Van-Tam, J.S., Venkatesan, S., Muthuri, S.G., Myles, P.R., Neuraminidase inhibitors: who, when, where?. Clin Microbiol Infect 21 (2015), 222–225 Careful analysis of the conflicting reports on the clinical effectiveness of influenza neuraminidase inhibitors. Summarizes methodological limitations of recent clinical articles, including the Cochrane analysis [3] and the PRIDE study performed on a large data set collected during the 2009 pandemic [5].
7. 7 Krug, R.M., Aramini, J.M., Emerging antiviral targets for influenza A virus. Trends Pharmacol Sci 30 (2009), 269–277.
8. 8 Watanabe, T., Kawaoka, Y., Influenza virus–host interactomes as a basis for antiviral drug development. Curr Opin Virol 14 (2015), 71–78.
9. 9 Moss, R.B., Hansen, C., Sanders, R.L., Hawley, S., Li, T., Steigbigel, R.T., A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 206 (2012), 1844–1851.
10. 10 Kim, J.H., Resende, R., Wennekes, T., Chen, H.M., Bance, N., Buchini, S., Watts, A.G., Pilling, P., Streltsov, V.A., Petric, M., Liggins, R., Barrett, S., McKimm-Breschkin, J.L., Niikura, M., Withers, S.G., Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. Science 340 (2013), 71–75.
11. 11 Wang, J., Li, F., Ma, C., Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Biopolymers 104 (2015), 291–309.
12. 12 Wang, J., Ma, C., Wang, J., Jo, H., Canturk, B., Fiorin, G., Pinto, L.H., Lamb, R.A., Klein, M.L., DeGrado, W.F., Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. J Med Chem 56 (2013), 2804–2812.
13. 13 Corti, D., Lanzavecchia, A., Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31 (2013), 705–742.
14. 14• Lee, P.S., Wilson, I.A., Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr Top Microbiol Immunol 386 (2015), 323–341 Excellent review on broadly-neutralizing anti-HA antibodies. Provides relevant background for non-experts besides a detailed description of antibody binding sites.
15. 15 Dreyfus, C., Laursen, N.S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D.C., Lee, J.H., Metlagel, Z., Bujny, M.V., Jongeneelen, M., van der Vlugt, R., Lamrani, M., Korse, H.J., Geelen, E., Sahin, Ö., Sieuwerts, M., Brakenhoff, J.P., Vogels, R., Li, O.T., Poon, L.L., Peiris, M., Koudstaal, W., Ward, A.B., Wilson, I.A., Goudsmit, J., Friesen, R.H., Highly conserved protective epitopes on influenza B viruses. Science 337 (2012), 1343–1348.
16. 16 DiLillo, D.J., Palese, P., Wilson, P.C., Ravetch, J.V., Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126 (2016), 605–610.
17. 17 Tharakaraman, K., Subramanian, V., Cain, D., Sasisekharan, V., Sasisekharan, R., Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell Host Microbe 15 (2014), 644–651.
18. 18 Gupta, P., Kamath, A., Park, S., Chiu, H., Lutman, J., Maia, M., Tan, M.W., Xu, M., Swem, L., Deng, R., Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. MAbs 8 (2016), 991–997.
19. 19 McKimm-Breschkin, J.L., Fry, A.M., Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res 129 (2016), 21–38.
20. 20 Badani, H., Garry, R.F., Wimley, W.C., Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. Biochim Biophys Acta 1838 (2014), 2180–2197.
21. 21 Vanderlinden, E., Naesens, L., Emerging antiviral strategies to interfere with influenza virus entry. Med Res Rev 34 (2014), 301–339.
22. 22 Russell, R.J., Kerry, P.S., Stevens, D.J., Steinhauer, D.A., Martin, S.R., Gamblin, S.J., Skehel, J.J., Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A 105 (2008), 17736–17741.
23. 23 Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., Rossignol, J.F., Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 14 (2014), 609–618.
24. 24 Rossignol, J.F., Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 110 (2014), 94–103.
25. 25 Te Velthuis, A.J., Fodor, E., Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat Rev Microbiol 14 (2016), 479–493.
26. 26•• Pflug, A., Guilligay, D., Reich, S., Cusack, S., Structure of influenza A polymerase bound to the viral RNA promoter. Nature 516 (2014), 355–360 A landmark in influenza research. The first crystal structures of the large influenza polymerase heterotrimer, bound to the vRNA promoter. Provides the first structural insight into the catalytic centre of PB1, which includes the NTP binding site. Proposes a structure-based model for viral RNA elongation.
27. ••]. By comparison between influenza A and B polymerase crystal structures, a model is proposed for the concerted action between the cap-binding PB2 subunit and PA endonuclease, which face each other during ‘cap-snatching’, after which the PB2-CBD rotates to direct the capped primer towards the PB1 catalytic site.
28. ••], the apo-complex shows a dramatic conformational difference due to ‘en bloc’ rotation of the part of PB2 containing the CBD.
29. 29• Thierry, E., Guilligay, D., Kosinski, J., Bock, T., Gaudon, S., Round, A., Pflug, A., Hengrung, N., El Omari, K., Baudin, F., Hart, D.J., Beck, M., Cusack, S., Influenza polymerase can adopt an alternative configuration involving a radical repacking of PB2 domains. Mol Cell 61 (2016), 125–137 Crystal structure of the influenza polymerase heterotrimer bound to a 5ʹ cRNA fragment. Provides further details on the pronounced structural flexibility of this protein complex.
30. 30 Stevaert, A., Naesens, L., The influenza virus polymerase complex: an update on its structure, functions and significance for antiviral drug design. Med Res Rev, 2016, 10.1002/med.21401 (in press).
31. 31 Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.L., Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100 (2013), 446–454.
32. 32 Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., Shiraki, K., Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49 (2005), 981–986.
33. 33 Naesens, L., Guddat, L.W., Keough, D.T., van Kuilenburg, A.B., Meijer, J., Vande Voorde, J., Balzarini, J., Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol 84 (2013), 615–629.
34. 34 Sangawa, H., Komeno, T., Nishikawa, H., Yoshida, A., Takahashi, K., Nomura, N., Furuta, Y., Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57 (2013), 5202–5208.
35. 35 Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., Deval, J., The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS ONE, 8, 2013, e68347.
36. 36 Baranovich, T., Wong, S.S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., Govorkova, E.A., T-705 (Favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87 (2013), 3741–3751.
37. 37 Cheung, P.P., Watson, S.J., Choy, K.T., Fun Sia, S., Wong, D.D., Poon, L.L., Kellam, P., Guan, Y., Malik Peiris, J.S., Yen, H.L., Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun, 5, 2014, 4794.
38. 38•• Clark, M.P., Ledeboer, M.W., Davies, I., Byrn, R.A., Jones, S.M., Perola, E., Tsai, A., Jacobs, M., Nti-Addae, K., Bandarage, U.K., Boyd, M.J., Bethiel, R.S., Court, J.J., Deng, H., Duffy, J.P., Dorsch, W.A., Farmer, L.J., Gao, H., Gu, W., Jackson, K., Jacobs, D.H., Kennedy, J.M., Ledford, B., Liang, J., Maltais, F., Murcko, M., Wang, T., Wannamaker, M.W., Bennett, H.B., Leeman, J.R., McNeil, C., Taylor, W.P., Memmott, C., Jiang, M., Rijnbrand, R., Bral, C., Germann, U., Nezami, A., Zhang, Y., Salituro, F.G., Bennani, Y.L., Charifson, P.S., Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem 57 (2014), 6668–6678 Describes the discovery and structure-guided optimization process of the influenza A-specific PB2-CBD blocker VX-787, which is in Phase 2 clinical trials. Cocrystallization revealed that VX-787 possesses two main structural components: optimal hydrophobic interactions with the methylated guanine-sandwiching and surrounding aromatic residues within the PB2-CBD, and a carboxylate group that mimics the phosphate moiety of the capped RNA ligand.
39. 39 Guilligay, D., Tarendeau, F., Resa-Infante, P., Coloma, R., Crépin, T., Sehr, P., Lewis, J., Ruigrok, R.W., Ortín, J., Hart, D.J., Cusack, S., The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 15 (2008), 500–506.
40. 40 Byrn, R.A., Jones, S.M., Bennett, H.B., Bral, C., Clark, M.P., Jacobs, M.D., Kwong, A.D., Ledeboer, M.W., Leeman, J.R., McNeil, C.F., Murcko, M.A., Nezami, A., Perola, E., Rijnbrand, R., Saxena, K., Tsai, A.W., Zhou, Y., Charifson, P.S., Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 59 (2015), 1569–1582.
41. 41• Xie, L., Wartchow, C., Shia, S., Uehara, K., Steffek, M., Warne, R., Sutton, J., Muiru, G.T., Leonard, V.H., Bussiere, D.E., Ma, X., Molecular basis of mRNA cap recognition by influenza B polymerase PB2 subunit. J Biol Chem 291 (2016), 363–370 Using crystallography, the authors identified structural differences in the PB2-CBDs of influenza A and B viruses, explaining why the influenza B protein displays broader capped RNA recognition. This insight is important to design PB2-CBD blockers with activity against influenza A and B.
42. 42 Liu, Y., Yang, Y., Fan, J., He, R., Luo, M., Zheng, X., The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism. J Biol Chem 290 (2015), 9141–9149.
43. 43 Wakai, C., Iwama, M., Mizumoto, K., Nagata, K., Recognition of cap structure by influenza B virus RNA polymerase is less dependent on the methyl residue than recognition by influenza A virus polymerase. J Virol 85 (2011), 7504–7512.
44. 44 Dias, A., Bouvier, D., Crépin, T., McCarthy, A.A., Hart, D.J., Baudin, F., Cusack, S., Ruigrok, R.W., The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458 (2009), 914–918.
45. 45 Yuan, P., Bartlam, M., Lou, Z., Chen, S., Zhou, J., He, X., Lv, Z., Ge, R., Li, X., Deng, T., Fodor, E., Rao, Z., Liu, Y., Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458 (2009), 909–913.
46. 46 DuBois, R.M., Slavish, P.J., Baughman, B.M., Yun, M.K., Bao, J., Webby, R.J., Webb, T.R., White, S.W., Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog, 8, 2012, e1002830.
47. 47 Kowalinski, E., Zubieta, C., Wolkerstorfer, A., Szolar, O.H., Ruigrok, R.W., Cusack, S., Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase. PLoS Pathog, 8, 2012, e1002831.
48. 7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 38 (1994), 2827–2837.
49. 49 Nakazawa, M., Kadowaki, S.E., Watanabe, I., Kadowaki, Y., Takei, M., Fukuda, H., PA subunit of RNA polymerase as a promising target for anti-influenza virus agents. Antiviral Res 78 (2008), 194–201.
50. 50 Stevaert, A., Dallocchio, R., Dessì, A., Pala, N., Rogolino, D., Sechi, M., Naesens, L., Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease. J Virol 87 (2013), 10524–10538.
51. 51 Song, M.S., Kumar, G., Shadrick, W.R., Zhou, W., Jeevan, T., Li, Z., Slavish, P.J., Fabrizio, T.P., Yoon, S.W., Webb, T.R., Webby, R.J., White, S.W., Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor. Proc Natl Acad Sci U S A 113 (2016), 3669–3674.
52. 52 Bauman, J.D., Patel, D., Baker, S.F., Vijayan, R.S., Xiang, A., Parhi, A.K., Martínez-Sobrido, L., LaVoie, E.J., Das, K., Arnold, E., Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors. ACS Chem Biol 8 (2013), 2501–2508.
53. 53 Su, C.Y., Cheng, T.J., Lin, M.I., Wang, S.Y., Huang, W.I., Lin-Chu, S.Y., Chen, Y.H., Wu, C.Y., Lai, M.M., Cheng, W.C., Wu, Y.T., Tsai, M.D., Cheng, Y.S., Wong, C.H., High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci U S A 107 (2010), 19151–19156.
54. 54 Ortigoza, M.B., Dibben, O., Maamary, J., Martínez-Gil, L., Leyva-Grado, V.H., Abreu, P. Jr., Ayllon, J., Palese, P., Shaw, M.L., A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog, 8, 2012, e1002668.
55. 55 He, X., Zhou, J., Bartlam, M., Zhang, R., Ma, J., Lou, Z., Li, X., Li, J., Joachimiak, A., Zeng, Z., Ge, R., Rao, Z., Liu, Y., Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 454 (2008), 1123–1126.
56. 56 Obayashi, E., Yoshida, H., Kawai, F., Shibayama, N., Kawaguchi, A., Nagata, K., Tame, J.R., Park, S.Y., The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 454 (2008), 1127–1131.
57. 57 Muratore, G., Goracci, L., Mercorelli, B., Foeglein, Á., Digard, P., Cruciani, G., Palù, G., Loregian, A., Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A 109 (2012), 6247–6252.
58. N interaction inhibitors, and achieved one optimized molecule with superior potency. Relevant article to acquire an update on this original class of inhibitors.
59. 59 Yuan, S., Chu, H., Zhao, H., Zhang, K., Singh, K., Chow, B.K., Kao, R.Y., Zhou, J., Zheng, B.J., Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase. Antiviral Res 125 (2016), 34–42.
60. 60 Kakisaka, M., Sasaki, Y., Yamada, K., Kondoh, Y., Hikono, H., Osada, H., Tomii, K., Saito, T., Aida, Y., A novel antiviral target structure involved in the RNA binding, dimerization, and nuclear export functions of the influenza A virus nucleoprotein. PLoS Pathog, 11, 2015, e1005062.
61. 61 Gerritz, S.W., Cianci, C., Kim, S., Pearce, B.C., Deminie, C., Discotto, L., McAuliffe, B., Minassian, B.F., Shi, S., Zhu, S., Zhai, W., Pendri, A., Li, G., Poss, M.A., Edavettal, S., McDonnell, P.A., Lewis, H.A., Maskos, K., Mörtl, M., Kiefersauer, R., Steinbacher, S., Baldwin, E.T., Metzler, W., Bryson, J., Healy, M.D., Philip, T., Zoeckler, M., Schartman, R., Sinz, M., Leyva-Grado, V.H., Hoffmann, H.H., Langley, D.R., Meanwell, N.A., Krystal, M., Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A 108 (2011), 15366–15371.
62. 62• Liu, C.L., Hung, H.C., Lo, S.C., Chiang, C.H., Chen, I.J., Hsu, J.T., Hou, M.H., Using mutagenesis to explore conserved residues in the RNA-binding groove of influenza A virus nucleoprotein for antiviral drug development. Sci Rep, 6, 2016, 21662 To achieve NP inhibitors with broad anti-influenza activity and a high resistance barrier, conserved NP regions are the most relevant. These authors investigated the conserved RNA binding groove and analysed the role of its individual residues in RNA binding. By focussing on one essential residue (Y148), the authors identified curcumin as an inhibitor of RNA binding by NP, and a potential lead for further drug development.
63. 63 Lejal, N., Tarus, B., Bouguyon, E., Chenavas, S., Bertho, N., Delmas, B., Ruigrok, R.W., Di Primo, C., Slama-Schwok, A., Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother 57 (2013), 2231–2242.
64. 64 Tharakaraman, K., Subramanian, V., Viswanathan, K., Sloan, S., Yen, H.L., Barnard, D.L., Leung, Y.H., Szretter, K.J., Koch, T.J., Delaney, J.C., Babcock, G.J., Wogan, G.N., Sasisekharan, R., Shriver, Z., A broadly neutralizing human monoclonal antibody is effective against H7N9. Proc Natl Acad Sci U S A 112 (2015), 10890–10895.
65. 65 Kao, R.Y., Yang, D., Lau, L.S., Tsui, W.H., Hu, L., Dai, J., Chan, M.P., Chan, C.M., Wang, P., Zheng, B.J., Sun, J., Huang, J.D., Madar, J., Chen, G., Chen, H., Guan, Y., Yuen, K.Y., Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28 (2010), 600–605.